SAPHNELO systemic lupus erythematosus Japan Post-Marketing Surveillance (PMS)

Trial Identifier:	D3461C00022
Sponsor:	AstraZeneca
Start Date:	December 2021
Primary Completion Date:	November 2025
Study Completion Date:	November 2025
Condition:	Lupus

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Japan	Ehime, Japan
Japan	Gifu, Japan
Japan	Shimane, Japan
Japan	Tokushima, Japan
Japan	Wakayama, Japan
Japan	Yamagata, Japan

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.